Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEOFree Report) from a sell rating to a hold rating in a report published on Friday.

Other analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Get Our Latest Report on ABEO

Abeona Therapeutics Trading Up 1.2 %

Shares of Abeona Therapeutics stock opened at $5.70 on Friday. The company’s fifty day moving average is $6.18 and its two-hundred day moving average is $5.51. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $9.01. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market capitalization of $247.78 million, a P/E ratio of -2.12 and a beta of 1.44.

Hedge Funds Weigh In On Abeona Therapeutics

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its holdings in Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after acquiring an additional 429,456 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth $1,732,000. abrdn plc increased its holdings in shares of Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Western Standard LLC lifted its stake in shares of Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Read More

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.